The purpose of this study is to compare the effects of TNFerade™ Biologic with 5-FU and radiation therapy with 5-FU and radiation therapy alone on patients with pancreatic cancer to see which is better. There are two parts to this study. The first part was called the dose-escalation phase that is completed. In the second part of the study, all participants will get 5-FU and radiation therapy, followed by gemcitabine therapy. TNFerade biologic will be administered by direct intratumoral injection using endoscopic ultrasound (EUS)-guided fine needle injection. TNFerade biologic (AdGVEGR.TNF.11D) is a replication-deficient serotype 5 adenovirus vector devoid of the basic integrating and replicating machinery (E1, E4, and partial E3 genes), which provides a high gene transfer efficiency. The rationale for the proposed study is that the addition of TNFerade biologic to standard therapy (external radiotherapy and 5-FU, followed by gemcitabine or gemcitabine/erlotinib maintenance therapy) may improve local control, reduce regional recurrences and improve quality of life and survival. Possible Side effects includes; fatigue, fever, nausea, inflammation of the esophagus, vomiting, chills, rapid heartbeat, weakness, pain, and anorexia the most frequent side effects considered related to TNFerade? Biologic. The most common side effects that were thought to be possibly caused by TNFerade? Biologic included fever, chills, nausea, fatigue, anorexia, vomiting, pain at the site of injection, low blood pressure, and diarrhea

The purpose of this study is to compare the effects of TNFerade™ Biologic with 5-FU and radiation therapy with 5-FU and radiation therapy alone on patients with pancreatic cancer to see which is better. There are two parts to this study. The first part was called the dose-escalation phase that is completed. In the second part of the study, all participants will get 5-FU and radiation therapy, followed by gemcitabine therapy. TNFerade biologic will be administered by direct intratumoral injection using endoscopic ultrasound (EUS)-guided fine needle injection. TNFerade biologic (AdGVEGR.TNF.11D) is a replication-deficient serotype 5 adenovirus vector devoid of the basic integrating and replicating machinery (E1, E4, and partial E3 genes), which provides a high gene transfer efficiency. The rationale for the proposed study is that the addition of TNFerade biologic to standard therapy (external radiotherapy and 5-FU, followed by gemcitabine or gemcitabine/erlotinib maintenance therapy) may improve local control, reduce regional recurrences and improve quality of life and survival. Possible Side effects includes; fatigue, fever, nausea, inflammation of the esophagus, vomiting, chills, rapid heartbeat, weakness, pain, and anorexia the most frequent side effects considered related to TNFerade? Biologic. The most common side effects that were thought to be possibly caused by TNFerade? Biologic included fever, chills, nausea, fatigue, anorexia, vomiting, pain at the site of injection, low blood pressure, and diarrhea